News

January 17, 2012 – Nonstop nosebleeds can be serious and frightening, often sending people to the emergency room, where their noses are packed with gauze. When that doesn’t work, nosebleeds can be halted by injecting microscopic particles – made of the same material as a kitchen sponge – into the arteries that supply the nose.

Home January 17, 2012
Home
News

January 17, 2012 β€” Killing tumors by freezing them can add precious time to the lives of women with ovarian cancer that has spread to other parts of the body. Minimally invasive cryoablation extends lives and is cost-effective, according to a study being presented at the 4th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).

Home January 17, 2012
Home
News

January 17, 2012 β€” The U.S. Food and Drug Administration (FDA) expanded the approved usage for an endovascular graft manufactured by W.L. Gore and Associates Inc. to include treatment of life-threatening tears or ruptures of the aorta (thoracic aortic transection).

Home January 17, 2012
Home
News

January 16, 2012 β€” Endosense has announced the European launch of the TactiCath 75 force-sensing ablation catheter as well as results of the EFFICAS clinical study of contact force-sensing in catheter ablation procedures.

Home January 16, 2012
Home
News

January 16, 2012 β€” Philips Healthcare announced the enrollment of the first patients in its CHILL-MI clinical study. The RAPID MI-ICE trial showed a 38 percent reduction in infarct size in STEMI patients who were cooled to a temperature of less than 35Β° C prior to performing angioplasty.

Home January 16, 2012
Home
Technology

January 12, 2012 β€” Clinical analytics company Humedica announced the launch of a predictive analytic model that identifies patients at high-risk for a congestive heart failure (CHF) hospitalization.

Home January 13, 2012
Home
News

January 13, 2012 β€” Amorcyte Inc., a NeoStem Inc. company, announced the expansion of intellectual property protection around its lead product candidate, AMR-001, with the grant of U.S. patent number 8,088,370 by the United States Patent and Trademark Office. Amorcyte's first issued patent (7,794,705) entitled "Compositions and Methods of Vascular Injury Repair," protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction (AMI). The new patent covers the use of AMR-001 in the repair of any vascular injury caused by vascular insufficiency, and effectively expands the breadth of the patented claims beyond the current target indications for AMR-001.

Home January 13, 2012
Home
News

January 13, 2012 – The U.S. Food and Drug Administration (FDA) is updating healthcare professionals and the public about preliminary findings from ongoing investigations following the voluntary recall of CardioGen-82 last July by the manufacturer, Bracco Diagnostics. CardioGen-82 consists of a generator that is used at clinical sites to produce rubidium (Rb)-82 chloride injection. A CardioGen-82 positron emission tomography (PET) scan is one of a variety of nuclear medicine scans that use radioactive drugs to evaluate myocardial perfusion.

Home January 13, 2012
Home
Feature

January 12, 2011 – U.S. healthcare spending experienced historically low rates of growth in 2009 and 2010 according to the annual report of national health expenditures (NHE) published in the January issue of the journal Health Affairs.

Home January 12, 2012
Home
News

January 12, 2012 – Geoffrey A. Rose, M.D., FASE, FACC, was recently appointed chairperson of the Intersocietal Accreditation Commission (IAC). Headquartered in Ellicott City, Md., the IAC is a national, nonprofit organization in operation to evaluate and accredit medical facilities.

Home January 12, 2012
Home
News

January 12, 2012 – Stereotaxis Inc. (announced the completion of the first 50 clinical procedures using the company's new Niobe ES system to treat patients with a variety of complex cardiac arrhythmias. A majority of the first 50 cases were performed to treat atrial fibrillation (AF), the most common type of cardiac arrhythmia. Positive initial results with the Niobe ES system in Europe demonstrate that the average time for completion of mapping and ablation for the initial AF patients was 69 minutes. The data will be featured at the Boston Atrial Fibrillation Symposium 2012 to be held on January 12-14, 2012.

Home January 12, 2012
Home
Feature

January 12, 2012 – Access to capital, a burdensome and uncertain regulatory environment, and lack of innovation and productivity in research and development are the biggest threats to the biomedical industry's growth over the next five years, according to biomedical company CEOs surveyed by CHI-California Healthcare Institute, BayBio and PwC US.

Home January 12, 2012
Home
Technology

January 12, 2012 – Masimo announced U.S. Food and Drug Administration (FDA) 510(k) clearance and full market commercial launch of the Masimo Pronto-7β€”a palm-sized handheld device designed for quick and easy noninvasive spot-checking of total hemoglobin (SpHb), SpO2, pulse rate, and perfusion index.

Home January 12, 2012
Home
Technology

January 12, 2012 β€” Simbionix USA Corp. recently announced advanced virtual reality (VR) simulators that can communicate in Chinese, Japanese and Russian, in addition to English.

Home January 12, 2012
Home
News

January 12, 2012 β€” A project led by The American Society of Echocardiography (ASE) will utilize the latest technological innovations in the field to bring cardiovascular ultrasound to rural India.

Home January 12, 2012
Home
Subscribe Now